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KEYNOTE ADDRESS 
The Role of Exenatide in 
Managing Cardiovascular Risks 
and Complications in Patients 
with Type 2 Diabetes 
AIM OF PRESENTATION  
 This presentation is based on a systematic 
review which examines the role of 
exenatide twice daily (BID) in managing 
cardiovascular risks and complications in 
patients with type 2 diabetes.  
 
INTRODUCTION 
 Type 2 diabetes is a progressive metabolic 
disorder of multiple aetiology 
 It is characterised by defects in insulin 
secretion and/or insulin action in peripheral 
tissues leading to chronic hyperglycaemia 
[1]. 
 Patients with type 2 diabetes are at greater 
risk of developing cardiovascular disease 
(CVD).  
INTRODUCTION CONTD 
 According to Saraiva and Sposito [2]; 
 about 68% of people over 65 yrs of age with 
diabetes die of some form of cardiovascualr 
disease 
 CVD deaths amongst adults with diabetes 
are 2 to 4 times higher than those without 
diabetes.  
 INTRODUCTION CONTD 
 
 Some observational studies have demonstrated 
that a higher glycated haemoglobin (HbA1c) level 
was associated with increased risks of 
cardiovascular diseases and deaths. 
 However, the underlying mechanisms remain 
complex [3,4]. 
 The progressive nature of type 2 diabetes despite 
the use of diet, physical activity and current 
therapies such as metformin, sulfonylurea and 
insulin may explain why therapeutic requirements 
tend to increase with time [1,5,6].  
 
INTRODUCTION CONTD 
 The addition of sulfonylurea and thiazolidinedione 
as treatment for diabetes are useful alternatives 
 However, these may have their limitations 
including; 
 The risk of hypoglycaemia  
 Potential for weight gain and oedema  
 Potential to reduce patient compliance [1,5].  
 Based on the above, new therapies which do not 
have the usual side effects of the current therapies 
have to be developed. 
 
INTRODUCTION CONTD 
 The NICE guideline [7] for blood glucose 
lowering therapy in adults with type 2 diabetes 
include the use of metformin alone, dual therapy 
and triple therapy (such as metformin, a 
Dipeptidyl peptidase – 4 – inhibitor and 
sulfonylurea). 
 If triple therapy is not effective, not tolerated or 
contraindicated;  
 consider combination therapy with metformin, a 
sulfonylurea and a Glucagon –like peptide –1 
(GLP – 1) mimetic.  
 
 
 
INTRODUCTION CONTD 
 To qualify for this treatment, patients should have; 
 body mass index (BMI) of ≥ 35kg/m2 
 have a lower BMI than 35kg/m2 and for whom 
insulin therapy would have significant 
occupational implications, or weight loss would 
benefit other significant obesity related co-
morbidities.  
INTRODUCTION CONTD 
  According to McCormack [8], human GLP 
–1 is produced by L–cells of the intestinal 
mucosa and is an incretin. 
 GLP–1 is a gastrointestinal hormone 
responsible for the enhanced secretion of 
insulin from the beta cells of the pancreas in 
response to food intake [9,10,11].  
INTRODUCTION CONTD 
 However, in patients with type 2 diabetes, the 
incretin effect is significantly impaired due to 
reduced production of GLP – 1, metablolism 
and/or impairment of their actions [12].  
 The incretin effect is the difference in insulin 
secretion from an oral glucose load compared with 
intravenous glucose administration 
 It results from the observation that intrajejunal 
glucose enhances greater insulin release than 
intravenous glucose administration [2,13,14]. 
 
 INTRODUCTION CONTD 
 GLP –1 receptor agonists such as exenatide 
significantly decrease glycated haemoglobin 
via; 
  suppressing glucagon production 
 delaying gastric emptying  
 reducing appetite and food intake by 
increasing satiety [9]. 
 
 INTRODUCTION CONTD 
 Exenatide is a 39 – amino acid peptide and is an 
incretin mimetic which was the first of the new 
incretin mimetic class of antihyperglycaemic 
agents to be marketed in the US and European 
Union [8,10].  
 Exenatide is a short acting agent which can be 
administered  subcutaneously twice daily 
(exenatide BID) although the extended release 
formulation can be administered once weekly 
(exenatide QW) [8]. 
 
METHOD 
 The literature search included the following; 
  a general scoping of the data bases which 
included; 
  EBSCO host, encompassing Academic search 
premier, Medline, Psychology and Behavioural 
sciences collection, PSYCINFO, 
SPORTDISCUSS and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) 
Plus. 
 
METHOD CONTD 
 However, the reviews found were either; 
 more than 5 years old 
 were narrative reviews 
 included liraglutide  
 were studies which were not randomised  
 The current systematic review is based only 
on randomised controlled studies.  
 
 
METHOD CONTD 
 The search strategy relied on published guidelines 
for reviews [15,16] and was based on the PICO 
framework; 
 Population (P) 
 Interventions (I) 
 Comparative interventions (C)  
 Outcomes (O)  
 The ‘Boolean’ search strategy allowing the 
combination of search terms. 
TABLE 1: LITERATURE SEARCH 
STRATEGY 
 
 
Database Dates covered Date searched Search Terms Hits 
EBSCO Host   2010 –  2016 20.03.15 Exenatide AND Diabetes OR 
Glycaemic control 
19,065 
EBSCO Host   2010 –  2016 20.03.15 GLP–1 AND Diabetes 7,841 
EBSCO Host   2010 –  2016 20.03.15 GLP–1 AND Diabetes AND 
Microvacular Complications 
92 
EBSCO Host   2010 –  2016 20.03.15 GLP–1 AND Diabetes AND 
Macrovacular Complications 
74 
EBSCO Host   2010 –  2016 20.03.15 Exenatide AND Diabetes OR 
GLP – 1 
10,643 
EBSCO Host   2010 –  2016 20.03.15 Type 2 Diabetes AND 
Exenatide  
1,695 
EBSCO Host   2010 –  2016 20.03.15 Type 2 Diabetes AND 
Exenatide twice daily 
289 
EBSCO Host   2010 –  2016 20.03.15 Type 2 Diabetes AND 
Exenatide twice daily AND 
Control 
169 
 
INCLUSION AND EXCLUSION 
CRITERIA 
  Studies included were those written in English and 
published between 2010 and 2016 only.  
 In addition, only randomised controlled studies 
were selected for review. 
 Studies which did not meet the inclusion criteria 
outlined above were excluded from the review. 
 The original hits were filtered and narrowed down 
using the above criteria. 
 
QUALITY ASSURANCE 
 This was based on the Scottish 
Intercollegiate Guidelines Network (SIGN) 
checklist for critical appraisal (Scottish 
Intercollegiate Guidelines Network (SIGN), 
[17] and my experience as a researcher. 
 
DATA ANALYSIS 
 On the basis of the inclusion and exclusion 
criteria, 19,065 articles including full articles and 
abstracts were initially found following a search of 
the databases (Table 1).  
 However, based on the use of various search 
terms, this was significantly narrowed to smaller 
numbers.  
 Of these, 11 articles which met the requirements 
for selection were included in the review (Table 
2). 
RESULTS 
 All the eleven studies 
[18,19,20,21,22,23,24,25,26,27,28] (Table 2) for 
this review were multicentre and randomised 
controlled studies involving patients with type 2 
diabetes. 
 While seven of the studies [18,20,21,22,24,26,27] 
were conducted in at least 2 countries, the 
remaining 4 [19,23,25,28] were conducted in Italy, 
Japan, the US and Germany respectively.  
RESULTS CONTD 
 However, all eleven studies had background 
treatment in addition to the intervention treatments 
except the study by Gastaldelli et al [18].  
 
 The background treatments included metformin 
and/or insulin glargine, pioglitazone, diet and 
exercise, and thiazolidinedione. Other background 
treatments were sulfonylurea and/or biguanide, 
thiazolidinedione and/or metformin. 
 
RESULTS CONTD. 
 The sample size of the studies ranged from 
54 to 1,019 while the length of study ranged 
from 12 weeks to 4½ years.  
 The duration of diabetes of the patients in 
the studies ranged from 1±2 to 12±7 years 
(Mean ± SD).  
EXENATIDE TWICE DAILY 
VERSUS PLACEBO  
 Exenatide twice daily were compared to placebo in 
seven of the 11 studies [18,19,20,21,22,23,24] (Table 
2). 
 Participants in the exenatide groups with metformin as 
one of the background treatments showed statistically 
significant decrease in body weight in five of the 
studies [19,20,21,22,23] compared to placebo group.  
 However, mean reductions in body weight were not 
statistically significant between exenatide and placebo 
groups in the studies by Gastaldelli et al [18] and 
Liutkus et al [24]. 
EXENATIDE TWICE DAILY 
VERSUS PLACEBO  
 The exenatide group in all the seven studies 
showed statistically significant decrease in HbA1c 
compared with the placebo group except for one 
study [22], where HbA1c reduction was not 
significantly different between the two groups 
(P=0.26).  
 There were no significant differences in lipid 
profile between the exenatide groups and the 
placebo group [19,21,23,24] except with respect to 
HDL cholesterol in the study by Kadowaki et al 
[23]  
 
 
 
EXENATIDE TWICE DAILY 
VERSUS PLACEBO  CONTD. 
 The Kadowaki et al [23] study showed that significant 
reduction in HDL cholesterol was statistically greater in 
both exenatide gps compared to placebo although no 
statistically significant difference was observed in total 
cholesterol, LDL-cholesterol and triglycerides.  
 However, systolic and diastolic BP decreased 
significantly in the exenatide group  compared to 
placebo group in two studies [19,21].  
 In another study [24], diastolic pressure was 
significantly reduced in both treatment gps, while 
systolic blood pressure remained relatively unchanged 
from baseline values. 
 
 
 EXENATIDE TWICE DAILY 
VERSUS OTHER CONTROLS 
 
 While one of the remaining 4 studies had placebo + 
lifestyle modification as control [25], the other 3 
studies were not placebo controlled [26,27,28].  
 The interventions included;  
 Exenatide + lifestyle modification versus placebo + 
lifestyle modification with metformin and/or 
sulfonylurea as background treatment [25]  
 Exenatide versus Glimepiride with metformin as 
background treatment [26,27]  
 Exenatide versus premixd insulin aspart with 
metformin as background treatment [28]. 
 EXENATIDE TWICE DAILY 
VERSUS OTHER CONTROLS 
 
 In all the 4 studies [25,26,27,28] (Table 2); 
 There were significantly better clinical outcomes in 
the exenatide groups compared with Glimepiride, 
premixed insulin aspart, placebo plus lifestyle 
modification programme  
 These were based on the specific outcomes measured 
by each study including; body weight, blood pressure, 
lipid profile and glycaemic control.  
 EXENATIDE TWICE DAILY 
VERSUS OTHER CONTROLS 
 
 With respect to HbA1c targets (<7% and <6.5%) 
exenatide twice daily was non inferior compared 
to premixed insulin aspart [28].  
 In addition, there were significant differences in 
favour of the exenatide groups compared with the 
glimepiride group with respect to HbA1c < 7% 
(P<0.0001) and HbA1c <6.5% (P=0.0001) [27].  
 The percentage of hypoglycaemia in the exenatide 
group was significantly (P<0.0001) lower than the 
glimepiride group [26].  
 
 EXENATIDE TWICE DAILY 
VERSUS OTHER CONTROLS 
 
 When compared with the placebo plus lifestyle, the 
exenatide plus lifestyle groups had significantly more 
participants who had HbA1c ≤6.5% (P=0.001) [25]. 
 The study by Simo et al [26] showed that a 
statistically significant proportion of exenatide treated 
patients achieved the HDL-cholesterol goal than 
glimepiride treated patients at 36 months (P=0.21).  
 In addition, systolic blood pressure (BP) [25,26,27] and 
diastolic BP [25,26] descreased significantly in the 
exenatide groups compared with controls. 
 
 
TABLE 2: SUMMARY OF 
STUDIES REVIEWED 
 
Citation Length 
of Study 
Study 
Type 
Sample 
Size 
Age 
(Years)  
Diabete
s 
duratio
n (Yrs) 
Back
grou
nd 
treat
ment 
Interve
ntion 
Glycaemic 
Control 
Lipid 
Profile 
Blood 
pressur
e and 
Heart 
rate 
Outcom
es/body 
weight 
Gastaldelli 
et al [18] 
24 weeks Randomise
d 
Controlled 
Study 
79 Exenatide 
(10 µg) 
59±2 
Exenatide 
(5 µg) 
57±2 
Placebo  
54±2 
  
  
  
2±3 
(Exenatide 
5µg) 
  
2±3 
(Exenatide 
10 µg) 
  
1±2 
(Placebo) 
– Exenatide 
twice 
daily 
versus  
Placebo 
Compared to 
placebo, 24 
wks of daily 
high or low 
dose exenatide 
treatment 
significantly 
reduced  
HbA1c 
(P<0.01) and 
fasting plasma 
glucose 
(P<0.05) 
–  – There were 
no 
differences 
in wt. 
changes 
between 
the two 
exenatide 
and 
placebo 
groups 
Derosa et 
al [19] 
4 years  Randomise
d 
Controlled 
Study 
174 57.1±7.6 7.8±3.2 Metfor
min 
Diet 
and 
exercis
e 
advise 
Exenatide 
twice 
daily 
versus  
Placebo 
Exenatide+ 
metformin 
were better 
than placebo+ 
metformin in 
decreasing 
HbA1c at 
12months 
(P<0.05). 
Similar trend 
was recorded 
for fasting 
blood glucose. 
No 
variation 
in lipd 
profile 
were 
observed 
in either of 
the 2 gps. 
Systolic 
and 
diastolic 
BP were 
not 
changed 
by 
placebo+ 
metformin, 
but 
decreased 
by 
treatment 
with 
exenatide+ 
metformin 
at 12 
months 
compared 
with point 
of 
randomisat
ion 
(P<0.05) 
Body mass 
and BMI 
obtained 
after 
9months 
and 
12months 
of 
exenatide+ 
metformin 
were lower 
than the 
ones 
obtained 
for 
placebo+ 
metformin 
gp (P<0.05 
and 
P<0.01 
respectivel
y) 
  
 
Rosenstoc
k et al 
[20] 
30 
weeks 
Randomis
ed 
Controlle
d Study 
259 59 ±9 
(Exenatide)  
59 ±10 
(Placebo)  
  
12 ±7 
(Exenatide)  
12 ±7 
 (Placebo)  
  
Insulin 
glargine, 
Metformin, 
Pioglitazone 
Exenatide 
twice daily 
versus  
Placebo 
Exenatide 
participants had 
greater HbA1C 
reductions 
compared with 
placebo 
participants at 
end point 
(P<0.001) 
– – Exenatide 
participa
nts lost 
more 
weight 
(P<0.05) 
Buse et al 
[21] 
30 
weeks 
Randomis
ed 
Controlled 
Study m 
259 59 ±9 
(Exenatide)  
59 ±10 
(Placebo)  
  
12 ±7 
(Exenatide)  
  
12 ±7 
(Placebo)  
  
Insulin glargine 
with or  without 
Metformin or 
Pioglitazone (or 
both agents) 
Exenatide 
twice daily 
versus  
Placebo 
HbA1c level 
decreased by 
1.74% with 
exenatide and 
1.04% with 
placebo 
(P<0.001). 
Proportion of 
participants who 
had minor 
hypoglycaemia 
were similar in 
both groups 
Concentrat
ion of 
triglycerid
es, LDL, 
HDL did 
not differ 
between 
the groups 
Systolic and 
diastolic 
pressures 
decreased 
(P<0.01 and 
P<0.001) 
respectively from 
basline with 
exenatide. 
Heart rate 
increased from 
baseline in the 
exenatide group  
Wt. 
decreasd 
by 1.8kg 
with 
exenatide 
and 
increased 
by 1.0kg 
with 
placebo  
Gill et al 
[22] 
12 
weeks 
Randomis
ed 
Controlled 
Study 
54 Exenatide 
57±11 
  
Placebo 54±10 
7 ±4 
(Exenatide)  
  
6 ±4 
(Placebo)  
  
Metformin, 
thiazolidinedion
e,  
Metformin+ 
thiazolidinedion
e. 
Exenatide 
twice daily 
 versus 
Placebo   
HbA1c reduction 
was not 
significantly 
different between 
the 2 gps 
(P=0.26) 
– Differences in 
heart rate between 
the 2 gps was not 
significant 
(P=0.16). 
Exenatide therapy 
showed trends 
towards lower 
systolic BP, but 
similar diastolic 
BP between the 
gps. 
There 
were 
significant 
difference
s (P<0.05) 
in body 
weight 
between 
exenatide 
and 
placebo 
gp  
  
 
 
 
Kadowaki 
et al [23] 
24 weeks Randomise
d 
Controlled 
Study 
179 58 ± 10 12.2±6.3 
(Exenatide 
5µg) 
  
11.6±7.0 
(Exenatide 
10 µg) 
  
12.4±6.5 
(Placebo) 
Sulfonylur
ea, 
  
Sulfonylur
ea and 
biguanide, 
Sulfonylur
ea and 
thiazolidin
e 
derivative 
Exenatide 
twice daily  
 versus 
Placebo 
The 
changes in 
HbA1c 
levels were 
significantl
y greater 
(P<0.001) 
in both 
exenatide 
gps than 
the 
placebo gp 
The 
reduction in 
HDL 
cholesterol 
was 
statistically  
greater in 
both 
exenatide 
gps (5 μg, 
P=0.020 
and 10 μg 
P=0.014) 
than 
placebo gp. 
No 
statistically 
significant 
differences 
were 
observed in 
total 
cholesterol, 
LDL 
cholesterol 
and 
triglyceride
s 
– Reduction 
in body 
weight 
were 
significantl
y greater 
(P=0.026) 
in 
exenatide 
10 μg gp, 
than 
placebo 
gp. 
Liutkus et 
al [24] 
26 weeks Randomise
d 
Controlled 
Study 
165 Exenatide 
(55±8) 
  
Placebo 
(54±9) 
Exenatide 
(6.3±4.2) 
  
Placebo 
(6.4±4.6) 
Thiazolidin
edione, 
Metformin 
+ 
Thiazolidin
edione 
Exenatide  
twice daily 
versus 
Placebo 
Exenatide 
showed 
superiority 
with 
respect to 
change in 
HbA1c 
(P<0.001) 
and fasting 
serum 
glucose 
(P=0.009) 
compared 
with 
placebo  
There were 
no 
signifinicant 
changes in 
fasting 
serum lipids 
between 
treatment 
gps 
Diastolic 
pressure 
was 
significant
ly reduced 
in both 
treatment 
gps, while 
systolic 
BP 
remained 
relatively 
unchange
d from 
baseline 
values. 
Mean 
reductions 
in body 
weight 
were not 
significantl
y different 
between 
treatments 
at endpoint 
Apovian 
et al [25] 
24 weeks Randomis
ed 
Controlle
d Study 
194 54.8 ± 9.5 Exenatide 
(5.7±5.5) 
  
Placebo 
(5.3±5.1) 
Metformi
n or 
Sulfonylu
rea or 
both 
Exenatide 
twice 
daily + 
Lifestyle 
modificati
on 
program
me 
  
Placebo + 
Lifestyle 
modificati
on 
program
me 
  
  
Significan
tly more 
participan
ts treated 
with 
exenatide  
+ lifestyle 
modificati
on had 
HbA1c 
≤6.5% at 
end point 
compared 
with 
placebo + 
lifestyle 
modificati
on 
(P=0.001) 
– Exenatide  
+ lifestyle 
modificati
on was 
associated 
with 
significant 
decrease 
in systolic 
and 
diastolic 
BP at 
24wks 
from 
baseline 
compared 
with 
placebo + 
lifestyle 
modificati
on 
(P<0.001; 
P=0.04 ) 
Exenatide  
+ lifestyle 
modificati
on had 
significant
ly more 
weight 
loss 
compared 
with 
placebo + 
lifestyle 
modificati
on 
(P<0.01) 
Simo et al 
[26] 
4½ years Randomise
d 
Controlled 
Study 
Exenatide 
(n=511) 
Glimepirid
e (n=508) 
18 – 85  5.8±4.8 
(Exenatide
)  
5.5±4.3 
(Glimepiri
de)  
  
Metformin Exenatide 
twice daily 
versus 
Glimepirid
e 
Symptoma
tic 
hypoglyca
emia was 
reported 
during 1 yr 
of study 
treatment 
by 13.5% 
(exenatide 
gp)  and 
39.0% 
(glimepirid
e gp) 
(P<0.0001
)  
A sig. 
greater 
proportion 
of 
exenatide 
treated 
patients 
achieved 
the HDL-
cholesterol 
goal than 
glimepirid
e treated 
patients at 
36 months 
(P=0.21) 
Between-
group 
differences 
were 
significantl
y in favor 
of 
exenatide 
for systolic 
BP (P < 
0.001), 
diastolic 
BP (P = 
0.023) 
Between-
group 
differences 
were 
significantl
y in favor 
of 
exenatide 
for body 
weight (P 
< 0.0001), 
waist 
circumfere
nce (P < 
0.001).  
  
 
 Gallwitz 
et al, [27] 
4½ years Randomis
ed 
Controlle
d Study 
Exenatide 
= 490 
Glimepiri
de= 487 
18 - 85 5.8±4.8 
(Exenatid
e)  
5.5±4.3 
(Glimepiri
de)  
  
Metformi
n 
Exenatide 
twice 
daily 
versus 
Glimepiri
de 
44% in Exe natide 
gp and 31% in 
Glimepiride gp 
achieved HbA1c 
<7% (P<0.0001). 
29% in exenatide 
gp and 18% in 
Glimepiride gp 
achieved HbA1c 
≤6.5% (P=0.0001). 
Significantly fewer 
patients reported 
hyperglycaemia in 
exenatide gp 
compared with 
glimepiride gp 
(P<0.0001) 
– Systolic 
pressure 
decreased 
significantly 
in the 
exenatide gp 
(P=0.006) 
but not in 
the 
glimepiride 
gp (P=0.096). 
Heart rate 
increased in 
the exenatide 
gp. 
Significant 
decrease 
(P<0.0001) in 
body weight in 
exenatide gp 
compared with 
glimepiride gp 
Gallwitz et 
al [28] 
26 weeks Randomise
d 
Controlled 
Study 
354 57±10 
(Exenatide
) 
  
57 ±9.9 
(PIA) 
  
  
5±4 
(Exenatide
)  
  
5±5(PIA) 
  
  
Metformin Exenatide 
twice daily 
versus 
Premixed 
Insulin 
Aspart 
(PIA) 
HbA1c targets <7% 
and <6.5% 
(Exenatide 
noninferior to PIA). 
Hypoglcaemic 
epiosdes with blood 
glucose 
≤3.0mmols/L were 
less frequent with 
exenatide BID 
– – Exenatide twice 
daily (Wt.loss 
=4.1±0.22kg) 
PIA (Wt.gain= 
1.0±0.22kg) 
SEM (P<0.001) 
DISCUSSION 
 The exact mechanisms of control of 
cardiovascular risks and complications by 
exenatide are complex and still evolving [11,12]. 
 However, the findings of this review would 
suggest that the influence of exenatide in 
managing cardiovascular risks and complications 
may be through its effect in reducing glycated 
haemoglobin (HbA1c), reducing body weight and 
blood pressure.  
 
 
DISCUSSION CONTD. 
 This view is supported by previous reports which 
revealed that the potential effects of exenatide may 
be through glycaemic control based on the link 
between HbA1c and cardiovascular events and 
evidence that tight glycaemic control and/or 
decrease in HbA1c has been shown to reduce 
microvascular risks and complications [1,8,11]. 
 
 DISCUSSION CONTD. 
 
 Another possible mechanism of the effect of exenatide 
on cardiovascular risks and complications may be its 
impact on body weight.  
 Based on the results of the studies reviewed, nine of 
the eleven studies showed significant decrease in body 
weight among participants in the exenatide group 
compared with placebo or control group.  
 Only  two studies [18,24] did not report statistically 
significant differences in body weight between 
exenatide group and control group.  
DISCUSSION CONTD. 
 While one of these studies had no background 
treatment [18], the other had thiazolidinedione, 
metformin plus thiazolidinedione [24].  
 Therefore, it would appear that exenatide is more 
effective in reducing body weight in patients with 
type 2 diabetes when used in combination with 
metformin than when used alone or in 
combination with thiazolidinedione. 
 
DISCUSSION CONTD. 
 Increases in body weight and body mass index in 
patients with type 2 diabetes have been reported to 
increase the risk of cardiovascualr diseases 
whereas reduction in body weight increases 
insulin sensitivity and reduces blood pressure 
[11,31].  
 Another mechanism of exenatide action on 
cardiovascular risks and complications may be its 
effect on the pathogenic link between type 2 
diabetes and atherosclerosis [12]. 
DISCUSSION CONTD. 
 The formation of advanced glycation endproducts 
(AGE) in patients with type 2 diabetes plays a key 
role in vascular damage and exenatide has been 
reported to ameliorate this deleterious effects of 
AGEs [12]. 
 According to Anagnostis et al [12], the main 
mechanism of the antihypertensive role of 
exenatide may be due to its effect on weight loss 
although the authors also alluded to the 
vasodilatory effects of GLP-1.  
DISCUSSION CONTD. 
 Although exenatide twice daily may improve 
blood pressure and certain lipid parameters, 
changes are often small and variable between 
studies [8,32].  
 In the present review, the studies which looked at 
the effect of exenatide twice daily on lipid profile 
[19,21,23,24,25,26,27] did not find any significant 
difference between the exenatide group and the 
control group except for HDL – cholesterol 
[23,26].  
 
CONCLUSION 
 Based on the findings of this review, it would 
appear that exenatide twice daily may be useful in 
managing cardiovascular risks and complications 
by reducing body weight, HbA1c and blood 
pressure.  
 In particular, the combination of exenatide with 
metformin was more effective in reducing body 
weight than using exenatide alone. 
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